CorMedix Inc
NASDAQ:CRMD
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
CorMedix Inc
NASDAQ:CRMD
|
517.6m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
934.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
257.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for CorMedix Inc is 88.5%, which is above its 3-year median of 78.3%.
Over the last 3 years, CorMedix Inc’s Gross Margin has increased from 85.7% to 88.5%. During this period, it reached a low of -64.8% on Jun 30, 2024 and a high of 100% on Sep 30, 2023.
